Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer

Blood

Volumn 108, Issue 2, 2006, Pages 525-535

  Van Ginderachter, Jo A ^a,b   Meerschaut, Sofie ^a   Liu, Yuanqing ^a   Brys, Lea ^a   De Groeve, Kurt ^a   Ghassabeh, Gholamreza Hassanzadeh ^a   Raes, Geert ^a   De Baetselier, Patrick ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRANULOCYTE; IN VITRO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 33745950451     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3777     Document Type: Article

References (72)

1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-274.
2. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728-5737.
3. + T cells. Blood. 2000;96:3838-3846.
4. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol. 2003;74:186-196.
5. Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004;172:464-474.
6. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003;102:2138-2145.
7. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678-689.
8. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. Prepublished on July 27, 2005, as DOI 10.1007/s00262-005-0048-z.
9. + myeloid cells. J Immunol. 2001;166:5398-5406.
10. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989-999.
11. Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170:270-278.
12. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880-4891.
13. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839-5849.
14. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044-3048.
15. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol. 2003;170:5064-5074.
16. Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type1/type2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533-6544.
17. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
18. Gordon S. Alternative activation of macrophages. Nature Rev Immunol. 2003;3:23-35.
19. Noël W, Raes G, Hassanzadeh Ghassabeh G, De Baetselier P, Beschin A. Alternatively activated macrophages during parasite infections. Trends Parasitol. 2004;20:126-133.
20. Brys L, Beschin A, Raes G, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol. 2005;174:6095-6104.
21. Loke P, MacDonald AS, Robb AO, Maizels RM, Allen JE. Alternatively activated macrophages induced by nematode infection inhibit proliferation via cell to cell contact. Eur J Immunol. 2000;30:2669-2678.
22. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
23. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol. 1992;149:2709-2714.
24. + cells in the development of antitumor immunity. Cancer Res. 2004;64:1130-1139.
25. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65:3437-3446.
26. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636-645.
27. Vanden Driessche T, Verschueren H, De Baetselier P. Association between MHC class I antigen expression and malignancy of murine T lymphoma variants. Invasion Metastasis. 1990;10:65-85.
28. Raes G, Van Ginderachter J, Liu YQ, et al. Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol Immunother. 1998;45:257-265.
29. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte- differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151:2399-2408.
30. de Bruijn MFTR, van Vianen W, Ploemacher RE, et al. Bone marrow cellular composition in Listeria monocytogenes infected mice detected using ER-MP12 and ER-MP20 antibodies: a flow cytometric alternative to differential cloning. J Immunol Meth. 1998;217:27-39.
31. Taylor PR, Brown GD, Geldhof AB, Martinez-Pomares L, Gordon S. Pattern recognition receptors and differentiation antigens define murine myeloid cell heterogeneity ex vivo. Eur J Immunol. 2003;33:2090-2097.
32. Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172:4410-4417.
33. Geldhof AB, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 2002;100:4049-4058.
34. absent dendritic cells with tolerogenic potential. J Immunol. 2005;174:4706-4717.
35. Raes G, De Baetselier P, Noël W, et al. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol. 2002;71:597-602.
36. Gratchev A, Guilot P, Hakiy N, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein βIG-H3. Scand J Immunol. 2001;53:386-392.
37. Watanabe K, Jose PJ, Rankin SM. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol. 2002;168:1911-1918.
38. Rehli M, Sulzbacher S, Pape S, et al. Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. J Immunol. 2005;174:7111-7122.
39. Raes G, Brys L, Dahal BK, et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol. 2005;77:321-327.
40. Scotton CJ, Martinez FO, Smelt MJ, et al. Transcriptional profiling reveals complex regulation of the monocyte IL-1β system by IL-13. J Immunol. 2005;174:834-845.
41. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100:5336-5341.
42. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287-292.
43. Thivierge M, Stankova J, Rola-Pleszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol. 2001;167:2855-2860.
44. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res. 2000;54:275-280.
45. Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by selenoprotein P in human plasma against peroxynitrite-mediated oxidation and nitration. Biol Chem. 1998;379:1201-1205.
46. D'Argenio G, Grossman A, Cosenza V, Valle ND, Mazzacca G, Bishop PD. Recombinant factor XIII improves established experimental colitis in rats. Dig Dis Sci. 2000;45:987-997.
47. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-553.
48. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748-759.
49. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII: I, structure, distribution, activation and function. Crit Rev Clin Lab Sci. 1996;33:357-421.
50. Blagoev B, Kratchmarova I, Nielsen MM, et al. Inhibition of adipocyte differentiation by resistin-like molecule α: biochemical characterization of its oligomeric nature. J Biol Chem. 2002;277:42011-42016.
51. Kishimoto Y, Hiraiwa M, O'Brien JS. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res. 1992;33:1255-1267.
52. Lee C-H, Evans RM. Peroxisome proliferators-activated receptor-gamma in macrophage lipid homeostasis. Trends Endocrinol Metabol. 2002;13:331-335.
53. 2 regulation of arachidonic acid mobilization. FEBS Lett. 2002;531:2-6.
54. Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW. Chemokine expression dynamics in mycobacterial (Type-1) and schistosomal (Type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol. 2001;158:1503-1515.
55. van Vliet SJ, van Liempt E, Saeland E, et al. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. Int Immunol. 2005;17:661-669.
56. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268.
57. Yang XY, Wang LH, Mihalic W, et al. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor γ activated by macrophage-derived 12/15 lipoxygenase ligands. J Biol Chem. 2002;277:3973-3978.
58. 2 regulation of arachidonic acid mobilization. FEBS Lett. 2002;531:2-6.
59. Hestdal K, Ruscetti FW, Ihle JN, et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol. 1991;147:22-28.
60. Yang L, DeBusk L, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409-421.
61. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1996;93:14833-14838.
62. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1:510-514.
63. Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev. 2000;177:141-149.
64. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.
65. El-Gayar S, Thuring-Nahler H, Pfeilschifter J, Rollinghoff M, Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J Immunol. 2003;171:4561-4568.
66. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
67. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
68. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64:275-290.
69. Shapiro AC, Wu D, Meydani SN. Eicosanoids derived from arachidonic and eicosapentaenoic acids inhibit T cell proliferative response. Prostaglandins. 1993;45:229-240.
70. Avis I, Martinez A, Tauler J, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005;65:4181-4190.
71. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 2004;23:100-108.
72. Hassanzadeh Ghassabeh G, De Baetselier P, Brys L, et al. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo during different pathologies. Blood. Prepublished on March 23, 2006, as DOI 10.1182/blood-2005-04-1485.